Clinical Trials Browser

Phase 2 × NSCLC × Tyrosine Kinase Inhibitors × Clear all

NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Phase 2 Active not recruiting

NSCLC